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Aim. Selection of patients for investigation of suspected colorectal cancer is difficult. One possible improvement may be to measure DNA isolated from exfoliated cells collected from the rectum. 

Method. This was a cohort study in a surgical clinic in the Royal Devon & Exeter Hospital, Devon, UK. Participants were aged ≥40 years referred for investigation of suspected colorectal cancer. Exclusion criteria were: inflammatory bowel disease, previous gastro-intestinal malignancy, or recent investigation. A sample of the mucocellular layer of the rectum was taken with an adapted proctoscope (the Colonix system). Haemoglobin, mean cell volume, ferritin, carcino-embryonic antigen and faecal occult bloods were tested. Analysis was by logistic regression.

Results. 828 patients were offered participation; 717 completed the investigations. Three were lost to follow-up. 72 (10%) had colorectal cancer. Exfoliated cell DNA was higher in cancer: median 5.4μg/ml (inter-quartile range 1.8,12), without cancer 2.0μg/ml (0.78,5.5), p<0.001. 
Seven variables were independently associated with cancer: age, odds-ratio 1.05 per year (95% confidence interval 1.02,1.08), p<0.001; DNA 1.05 per μg/ml (1.01,3.6), p=0.01; mean cell volume per fl 0.93 (0.89,0.97), p=0.001; carcino-embryonic antigen 1.02 per μg/l (1.00,1.04), p=0.02; male sex 2.0 (1.1,3.6), p=0.02, rectal bleeding 2.4 (1.3,4.5), p=0.007; positive faecal occult blood 6.7 (3.4, 13), p<0.001. 
The area under the receiver-operating characteristic curve for the DNA score was 0.65 (0.58 to 0.72)and for the seven-variable model 0.88 (CI 0.84 to 0.92). 




What is new in this paper






Over 30,000 new colorectal cancers (CRCs) are diagnosed annually in the UK, leading to over 16,000 deaths.1 Survival in the UK is poor in comparison with many other European countries. ADDIN EN.CITE 2-3 It has recently been estimated that over 1000 lives are lost annually from colorectal cancer in the UK, when compared with the European mean, and over 1600 when compared with the best in Europe.4 A significant factor contributing to this is late diagnosis.5 Currently, most patients are diagnosed after symptoms have developed, and after presentation to primary care.6 This will remain the case even after full introduction of the UK National Bowel Cancer Screening Programme, as only around one cancer in ten is identified by screening.7 

In primary care, CRC is difficult to diagnose, as most of the symptoms of cancer can also be experienced with benign conditions, such as irritable bowel syndrome or haemorrhoids. These are also more common than cancer. National Referral Guidelines for Suspected Cancer  have been introduced (NICE Criteria),  although they have a weak evidence base, and concentrate upon typical presentations of cancer.8-9 These guidelines are used to select patients for rapid investigation in the ‘two-week’ clinics (so named, as specialist opinion is guaranteed within that time). ADDIN EN.CITE 10-11 However, this system has led to the concern that a two tier system has been created, with patients not qualifying for referral to a two-week clinic suffering undue delays. ADDIN EN.CITE 12-14 Only half of patients with CRC report a symptom (or symptoms) that qualify for a referral to a two-week clinic.15 Indeed, only a quarter of all CRCs are identified by such a route.16

A particular problem in the diagnosis of CRC is the absence of an adequate test that can be used to select patients at higher risk from those presenting with a low-risk symptom, such as diarrhoea or abdominal pain.17 Primary care investigation generally includes measurement of the haemoglobin, though at least half of patients with CRC have a normal value.18 Similarly, faecal occult blood testing has inadequate sensitivity and specificity for reliable use.19 A symptom scoring system, the CAPER score, has been derived, but has not entered routine use.20 In secondary care, similar problems exist, with increasing numbers of referrals for suspected colorectal cancer, accompanied by a fall in the percentage of referred patients who have cancer. It would be attractive to identify low-risk patients in this population, who could avoid a colonoscopy. Another symptom scoring system has been derived, the SELVA score, but this has also not entered routine clinical practice.21 In one clinic, use of this score had considerable diagnostic accuracy, as shown by an area under the receiver-operating characteristic curve (AUC) of 0.86. However, a recent report from Welsh colorectal clinics found a lower performance, with an AUC of 0.75.22 Even so, this was regarded as being worthy of use for prioritisation of referred patients and acts as a comparator for our data.23

Recent studies have suggested that measurement of DNA in exfoliated material collected from the surface of the rectal mucosa may identify colorectal disease, including cancer. ADDIN EN.CITE 24-26 In dysplasia and neoplasia, normal systems controlling cell exfoliation and death break down, with exfoliated cells progressing distally in the mucocellular layer of the colon, eventually reaching the rectum.24 These cells can be collected from the surface of the rectal mucosa using a simple device that incorporates an inflatable elastic membrane. The device is inserted into the rectum through a proctoscope (the Colonix system). Earlier studies in 30 patients with colorectal cancer (28) or large polyps (2) demonstrated a mean DNA score of 15.1μg/ml in rectal samples, compared with 3.9μg/ml in 52 outpatients with a normal bowel.25 A second study included 66 patients with cancer, plus 110 healthy controls aged 50-70, reporting mean rectal DNA scores of 9.0 and 2.1μg/ml in cancer patients and controls respectively.26 Given this initial promise, we performed a study to examine the diagnostic accuracy of a developmental version of such a test in symptomatic patients referred for investigation of possible colorectal cancer. 

Patients and Methods
This was a cohort study performed at the Royal Devon & Exeter Hospital, in Exeter, Devon, UK, between May, 2008 and May 2009. This hospital provides investigation of suspected colorectal cancer for a population of around 400,000, receiving approximately 125-140 such referrals monthly. 
Participants
All new NHS patients aged ≥40 years were eligible if they had been referred for investigation of suspected colorectal cancer through the two-week wait system. Exclusion criteria were: previous confirmed inflammatory bowel disease, previous gastro-intestinal malignancy, or relevant investigation of the bowel within the previous six months. Patients were offered participation as soon as the referral letter was received, and participants gave signed consent. Recruitment into the study was not allowed to interfere with current clinical and management priorities, which required patients to be offered an appointment within the next available clinic or to be invited directly for colonoscopy. At times, this process was too efficient to allow participation in the study to be offered. 

Data collection
Consenting participants completed a questionnaire detailing their symptoms and regular medications. The questionnaire was posted with the appointment letter along with full study details, except when the clinic appointment date and study entry was agreed by telephone, when the questionnaire and consent process was completed in clinic. At the hospital appointment, the timings of their most recent alcohol and food intake and defecation were recorded. Blood samples were taken for haemoglobin, mean red cell volume (MCV), ferritin and carcino-embryonic antigen testing, and a Haemoccult™ kit for faecal occult blood testing (FOBT) was given to the participant. Results of these tests were accepted in lieu of repeat testing if samples had been taken in the thirty days before study entry. Participants were not excluded from the study if they declined blood or FOBT sampling. A sample of exfoliated material was collected by LM or ID using the Colonix system. This sampling was performed before rectal examination to minimise disturbance to the rectal contents. The sample was preserved in cell lysis buffer and sent to an off-site laboratory for DNA isolation and quantification using a Pico-Green assay and real-time polymerase chain reaction by AL. We also measured faecal contamination by measuring the optical absorbance value for the sample at 340nm, defining a value below 1.5 as low contamination and ≥1.5 as high contamination. Throughout the study the laboratory was blinded to the clinical outcome and the clinicians to the laboratory findings. 

Determination of the outcome
All patients were offered appropriate investigation of the bowel by colonoscopy or CT as advised by the assessing specialist, generally within 2-3 weeks. However, the outcome of cancer was defined as a colorectal cancer diagnosed within six months of entry into the study – this allowed for any cancers missed at initial investigation, or for cancers to become apparent in those who declined definitive investigation. Cancers were confirmed histologically, and their site and staging collected from the hospital records. Two groups required additional efforts to determine their outcome: firstly, treatment of large rectal polyps is currently undertaken in Cheltenham, Gloucestershire, UK, using specialist trans-anal endoscopic microsurgery. We obtained copies of histology from these operations. Second, some patients declined definitive investigation. Their six-month outcome was determined by checking both their primary care and hospital records for colorectal cancer. 

Analysis
The main method of determining association with cancer was logistic regression. All putative explanatory variables with a p-value ≤0.1 in univariable analysis entered multivariable logistic regression models. For the multivariable analyses, a p-value of 0.05 was chosen for significance. Data were incomplete for four variables: faecal occult blood (116 missing values, 16% of the total), carcino-embryonic antigen (43, 6%), ferritin (34, 5%), and mean cell volume (5, 1%). For the multivariable analyses, imputed values for missing data in these variables were created using multiple imputation by chained equations.27 No important differences were observed in odds-ratios between the imputed dataset and the original dataset (full details in Appendix A): we provide the imputed regression results here. Plausible interaction terms relating to sample contamination, recent alcohol use, recent defecation and use of non-steroidal anti-inflammatory drugs were added to the final model, and tested with likelihood ratio tests. We tested for evidence against linear relationships between the continuous predictors and the log odds of cancer status using fractional polynomials.28  A receiver-operating characteristic (ROC) curve was compiled for the final model, in both the original and imputed datasets. The areas under the curves in these were nearly identical: however, calculation of confidence intervals in imputed datasets is impossible so we report so we report ROC curve characteristics from the original dataset.  Analyses used Stata, version 10.29 





The study outline is shown in Figure 1. This shows patient recruitment, eligibility, withdrawals and losses to follow-up. The age and sex of participants, broken down by outcome, is shown in Table 1. The two samples lost in transport had leaked completely. 714 participants had both a DNA score and knowledge of their outcome.  

Diagnostic outcomes
72 participants (10%) had a colorectal cancer: 32 (44%) of these cancers were situated in the rectum, 18 of which were palpable, 17 (24%) in the sigmoid, 12 (17%) in the caecum and 11 (15%) elsewhere in the bowel. All were adenocarcinomas, and only one was identified belatedly – in a patient whose apparently benign rectal polyp was found to contain a cancer after trans-anal endoscopic microsurgery. The median age of those with cancer was 74 years (inter-quartile range 70, 80) and of those without cancer 70 years (62, 80), those with cancer being significantly older, p=0.006, Mann-Whitney test, and more likely to be male, p=0.014, chi2 test.

Eighteen patients (2.7%) had other malignancies identified: four pancreatic, three lymphomas, three neuroendocrine tumours, two squamous anal and two liver cancers, plus one each of stomach, gastro-intestinal stromal tumour, kidney and lung. Seventeen (2.4%) patients had new diagnoses of inflammatory bowel disease. Adenomatous polyps at least 1cm in diameter were found in 102 (14.9%) of patients, though in nine of these patients a colorectal cancer was also found. 






No adverse effects of the rectal sampling were noted, other than temporary discomfort for some participants during proctoscope introduction. The DNA scores are shown in Figure 2. The DNA score was significantly higher in those with cancer: median score in those with cancer 5.4μg/ml (inter-quartile range 1.8, 12), and in those without cancer 2.0μg/ml (0.78, 5.5), p<0.001, Mann-Whitney test. The mean (standard deviation) values were 7.5 (7.3) and 4.4μg/ml (5.6) respectively. Similar results were found for polymerase chain reaction amplification of DNA (results not shown). 
Eighteen samples may be unreliable, and were identified as so before unblinding of the data: four had problems with deflation or bursting of the membrane; one container leaked and the sample could only be retrieved from the outer bag, one sample was so heavily contaminated with faeces that pipetting was extremely difficult, and three had been overfilled with buffer (one cancer), producing an unknown level of dilution. A further nine (three cancers) had unrealistically low DNA scores in all three assays, so it is probable they were inadequate samples. These were all included in the main analysis, though subsidiary analyses (below) excluded them. 





Multivariable modelling using imputed values for the missing variables is shown in Table 3. No interactions were identified for contamination, use of non-steroidal anti-inflammatory drugs, or for recent food or alcohol intake, or for defecation within the two hours before clinic attendance. The ROC curve from the seven-variable model in Table 3 is shown in Figure 3. The area under the curve was 0.88 (CI 0.84 to 0.92). For the DNA value alone the area under the curve was 0.65 (0.58 to 0.72).

Multivariable analysis excluding the 18 potentially unreliable samples from analysis produced the same seven-variable model with similar odds-ratios. The area under the ROC curve was 0.90 (0.86 to 0.93), and for the DNA value alone it was 0.65 (0.58 to 0.72).






This study shows that DNA scores measured in exfoliated material from the rectum of patients at moderate risk are associated with colorectal cancer. However, the diagnostic power of DNA concentration when used alone was modest, but when added to other symptoms, blood test results and FOBTs – all of which are available in primary or secondary care – it became considerably stronger. 

Strengths and limitations
This study was conducted in a single hospital.  The percentage of patients diagnosed with cancer in our study is similar to previous reports, suggesting it was nationally representative.16 Only a proportion of eligible patients were offered study participation. This was simply because patients were given the next available appointment – which was often too soon to allow recruitment into the study: it is unlikely those offered participation were atypical. The two surgeons who collected samples rapidly assimilated experience in use of the cell capturing device during the study. Sampling was straightforward, though eighteen samples (2.5%) were probably inadequate, some from faults with the device or the buffer fluid, and others with DNA scores so low as to suggest the balloon may have failed to make contact with the rectal mucosa. If the Colonix system were to enter clinical use, such samples would require repeating, though this ‘failure rate’ compares favourably with tests such as cervical cytology, with the traditional smear test  having a failure rate of over 11%.31 Excluding these patients from analysis moderately improved the performance of the test. 

Thirty seven (4.9%) of the 754 eligible participants declined the test, though we do not know how many of these were specifically concerned about the technique for sampling of the rectal contents – some may have disliked rectal examination per se, or any type of proctoscopy. This percentage is much lower than the 16% who did not submit a FOBT. As well as missing data for FOBTs, there were a small number of patients without blood test results. The imputation methods to compensate for missing data followed standard practice, and the results were very similar with and without imputation, so it is unlikely this procedure introduced any important bias.27 Eighteen of the cancer patients had a palpable rectal tumour, which could interfere with sampling.  In practice, some of these patients would be identified clinically and would not require sampling.

One strength was the very thorough follow up, with only one patient wholly lost from study. Using an endpoint of cancer at six months allowed us to identify the one cancer missed on investigation, though no cancers were belatedly diagnosed in the few patients who declined investigation. It is a reasonable assumption that in a symptomatic population any colorectal cancer not identified because investigation was declined would have come to light within six months.32 

Comparison with previous literature
Two pilot studies reported mean DNA scores of 15.1 and 9μg/ml in those with cancer, though in fewer patients. ADDIN EN.CITE 25-26 The mean score in this study was 7.5μg/ml, though many fewer patients were excluded in the current study. DNA scores were skewed, and had a median of 5.4μg/ml. The cancer and non-cancer populations in the present study had overlapping DNA distributions, suggesting that using the DNA value on its own would have insufficient discriminatory power to allow safe decision making on the need for investigation. Although high DNA scores were observed in all heavily contaminated samples, such contamination did not alter the association between the DNA score and the presence of cancer.  Non-compliance with the restriction of food or alcohol did not alter the association either, implying that such restrictions may be unnecessary for future use of the test, thus making this test easier to use.

Place in colorectal cancer diagnosis
This study was performed in the referred population. It was efficient to do so, as a study in primary care would have had to be much larger to compensate for the relative rarity of cancer in that setting. The performance of the seven-item model was excellent. Few selection methods for colorectal cancer have been validated in either the low-risk population of primary care, or the moderate-risk referred population. The model in this study compares well with the CAPER and SELVA scores, which have arguably the largest evidence base. ADDIN EN.CITE 20-22 When the CAPER score was tested in a second primary care dataset the area under the ROC curve was 0.79 (data submitted for publication): the SELVA score, when tested in a referred population (similar to ours)  in Wales the area was 0.76.22  In the study reported here, the area below the ROC curve was 0.88, and 0.90 if unreliable samples are excluded. Furthermore, the ROC curve is steep on the left, an area with high specificity and low sensitivity. This would allow for rationalisation of further investigations. Arguably, many of the patients at this point on the curve could be spared colonoscopy and could be re-assessed clinically or investigated by minimal preparation computerised tomography or Barium enema.  This is particularly relevant, as colorectal cancer has been selected for increased rapid access to primary care diagnostics.33 Inevitably, this policy will yield more referrals, so any valid method of selecting those at very low risk could considerably reduce the total costs of investigation, estimated at over £200 million annually.34 This study was not designed to test the DNA score in inflammatory bowel disease but values were significantly higher in patients who were diagnosed with IBD.  Such a finding was not unexpected as colonocyte shedding is increased in inflammatory bowel disease. Our analysis labelled such patients correctly as without cancer, though definitive investigation in these patients was clearly of diagnostic value. Our pragmatic secondary analysis including patients with inflammatory bowel disease as a ‘positive’ outcome suggested that selection of patients in using our model would also correctly identify them for investigation. 






Rectal sampling has promise in the diagnosis of colorectal cancer. When combined with simple blood tests, age, sex and results of faecal occult blood tests the method presented has considerable ability to predict cancer. This combination may be particularly useful in triage of referrals for investigation, with the intention being to select those at very low risk, who can then be observed. A second cohort study in the referred population is ongoing. If its results are similar to those reported here, then serious consideration should be given to implementation of this diagnostic system. 
For the future, there may also be a role for use in primary care, but this will require further investigation. 
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Figure 1. Participation, eligibility, withdrawals and losses in the study


Note. The 828 initial participants were from approximately 1500 referrals: it was not possible to keep accurate figures for those in whom the logistics of offering a rapid appointment overrode the offer of study entry, as opposed to those who were offered study entry but declined. However, it was clear, that the second of these groups was much smaller than the former.
 
Table 1. Age and sex of participants














Table 2. Symptoms and investigation results

	Colorectal cancer (n=72)	Without colorectal cancer (n=642)	Total (n=714)
	Present	Absent	Present	Absent	Present	Absent
Number (%) reporting a symptom 
Rectal bleeding	44 (61)	28 (39)	266 (41)	376 (59)	310 (43)	404 (57)
Weight loss	27 (38)	45 (62)	192 (30)	450 (70)	219 (31)	495 (69)
Abdominal pain	30 (42)	42 (58)	286 (45)	356 (55)	316 (44)	398 (56)
Constipation	23 (32)	49 (68)	217 (34)	425 (66)	240 (34)	474 (66)
Diarrhoea	33 (46)	39 (54)	367 (57)	275 (43)	400 (56)	314 (44)
Investigations *
Positive faecal occult blood  	35 (59)	24 (41)	63 (12)	476 (88)	98 (16)	500 (84)
Blood tests *
	Mean 	S.D	Mean 	S.D	Mean 	S.D
Haemoglobin (g/dl) 	13.4	9.5	13.3	1.8	13.3	3.4
Mean cell volume (fl)	85.1	7.5	87.8	5.9	87.5	6.1
Ferritin (pmol/l)	147	351	128	120	130	159
Carcino-embryonic antigen  (μg/L)	53	178	3.2	13	8.1	59











Table 3. Multivariable analysis of diagnostic features for colorectal cancer

Feature	Odds ratio	95% confidence interval	P-value
Continuous variables
Age (years)	1.05	1.02 to 1.08	<0.001

DNA (μg/ml)	1.05	1.01 to 3.6	0.01
Mean red cell volume (fl)	0.93	0.89 to 0.97	0.001
Carcino-embryonic antigen  (μg/L)	1.02	1.00 to 1.04	0.02
Binary variables
Male sex	2.0	1.1 to 3.6	0.02
Rectal bleeding	2.4	1.3 to 4.5	0.007
Positive faecal occult blood test	6.7	3.4 to 13	<0.001










Appendix A. Technique for generation of imputed values.

This used multiple imputation by chained equations.27 No associations were observed between missing data for faecal occult bloods (the variable with the greatest number of missing values) and possible explanatory variables, such as age or sex, so we assumed the values were missing at random.  Two variables required transformation before generation of imputed values: ferritin by log transformation, and carcino-embryonic antigen by using the inverse. All variables that were significantly associated with cancer in logistic regression in the dataset with full values (n=570), with the addition of male sex, were included in the regression equations for imputation, as was the outcome variable, cancer.29 25 cycles of imputation were run, and the two transformed variables back-transformed. 










27 were ineligible for study

10 previous bowel cancer
5 recent bowel investigation




84 withdrew from study

37 declined rectal sampling
36 cancelled or failed to attend 
11 were admitted as an emergency

828 patients were offered participation and gave initial consent

717 patients had rectal sampling





2 samples lost in transit
1 declined investigation and moved away 
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